S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
66,000% upside on tiny biotech? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Having Trouble in Your Trading? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
66,000% upside on tiny biotech? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Having Trouble in Your Trading? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
66,000% upside on tiny biotech? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Having Trouble in Your Trading? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
66,000% upside on tiny biotech? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Having Trouble in Your Trading? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:CYCC

Cyclacel Pharmaceuticals (CYCC) Stock Forecast, Price & News

$0.65
0.00 (0.00%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.64
$0.67
50-Day Range
$0.52
$0.70
52-Week Range
$0.50
$2.41
Volume
13,621 shs
Average Volume
64,171 shs
Market Capitalization
$8.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Cyclacel Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,130.8% Upside
$8.00 Price Target
Short Interest
Bearish
4.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.64) to ($2.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars


CYCC stock logo

About Cyclacel Pharmaceuticals (NASDAQ:CYCC) Stock

Cyclacel Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It uses cell cycle, transcriptional regulation and DNA damage response biology to develop medicines for cancer and other proliferative diseases. The company builds a biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Receive CYCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyclacel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CYCC Stock News Headlines

The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Cyclacel Pharmaceuticals (NASDAQ: CYCC)
See More Headlines

CYCC Price History

CYCC Company Calendar

Last Earnings
3/06/2023
Today
6/02/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYCC
Employees
2,018
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+1,130.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-21,200,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.81 per share

Miscellaneous

Free Float
12,012,000
Market Cap
$8.15 million
Optionable
Not Optionable
Beta
1.11

Key Executives

  • Spiro Rombotis
    President, Chief Executive Officer & Director
  • Paul McBarron
    Secretary, Chief Operating & Financial Officer
  • Mark Kirschbaum
    Chief Medical Officer & Senior Vice President













CYCC Stock - Frequently Asked Questions

Should I buy or sell Cyclacel Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CYCC shares.
View CYCC analyst ratings
or view top-rated stocks.

What is Cyclacel Pharmaceuticals' stock price forecast for 2023?

2 brokers have issued twelve-month price targets for Cyclacel Pharmaceuticals' stock. Their CYCC share price forecasts range from $8.00 to $8.00. On average, they predict the company's stock price to reach $8.00 in the next year. This suggests a possible upside of 1,130.8% from the stock's current price.
View analysts price targets for CYCC
or view top-rated stocks among Wall Street analysts.

How have CYCC shares performed in 2023?

Cyclacel Pharmaceuticals' stock was trading at $0.6670 on January 1st, 2023. Since then, CYCC shares have decreased by 2.5% and is now trading at $0.65.
View the best growth stocks for 2023 here
.

When is Cyclacel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our CYCC earnings forecast
.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) announced its earnings results on Monday, March, 6th. The biotechnology company reported ($0.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.12.

When did Cyclacel Pharmaceuticals' stock split?

Shares of Cyclacel Pharmaceuticals reverse split on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Who are Cyclacel Pharmaceuticals' major shareholders?

Cyclacel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Schonfeld Strategic Advisors LLC (5.87%). Insiders that own company stock include Sam L Barker and Spiro George Rombotis.
View institutional ownership trends
.

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $0.65.

How much money does Cyclacel Pharmaceuticals make?

Cyclacel Pharmaceuticals (NASDAQ:CYCC) has a market capitalization of $8.15 million. The biotechnology company earns $-21,200,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis.

How many employees does Cyclacel Pharmaceuticals have?

The company employs 2,018 workers across the globe.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cyclacel.com. The biotechnology company can be reached via phone at (908) 517-7330, via email at ir@cyclacel.com, or via fax at 866-271-3466.

This page (NASDAQ:CYCC) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -